• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

野生型TP53预示胃癌患者预后不良。

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer.

作者信息

Deng Wenhong, Hao Qiongyu, Vadgama Jaydutt, Wu Yong

机构信息

Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Division of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, CA, USA.

出版信息

J Cancer Sci Clin Ther. 2021 Mar 18;5(1):134-153. doi: 10.26502/jcsct.50790107.

DOI:10.26502/jcsct.50790107
PMID:34950877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8694034/
Abstract

UNLABELLED

TP53 gene is often mutated in gastric cancer (GC), nonetheless its relationship with clinicopathological characteristics and prognosis is still unclear. Here, we sought to ascertain the difference in clinical phenotypes between TP53 wild-type and mutant tumors in confirmed gastric cancer patients. To this end, we analyzed TP53 mutation status of 415 TCGA GC patients in relation to their clinical and pathological features as well as prognosis. Longrank Test showed that the survival rate of gastric cancer patients with TP53 WT was significantly lower than that of TP53 mut. Compared with TP53 mut gastric cancer patients with low mRNA expression, TP53 WT patients with low mRNA expression have lower overall survival rate. The death risk of TP53 WT gastric cancer patients is 1.395 times that of TP53 mut gastric cancer patients. The death risk of TP53 mut gastric cancer patients is not related to age, and advanced age is not a risk factor. However, the death risk of TP53 WT patients with gastric cancer increases with age, and the death risk of patients over 70 years old is 1.899 times that of patients under 60 years old. These results suggest that the prognosis of elderly gastric cancer patients with TP53 WT is worse.

CONCLUSION

our results indicate that the status of TP53 mutation in GC is significantly correlated with clinical or molecular categories and that the prognosis of GC patients with WT TP53 is worse than that of patients with mutant TP53. Therefore, our data emphasize the importance of distinguishing TP53 WT to predict poor overall survival and relapse-free survival in patients with GC.

摘要

未标记

TP53基因在胃癌（GC）中常发生突变，但其与临床病理特征及预后的关系仍不明确。在此，我们试图确定确诊的胃癌患者中TP53野生型和突变型肿瘤之间的临床表型差异。为此，我们分析了415例TCGA胃癌患者的TP53突变状态与其临床病理特征及预后的关系。长秩检验显示，TP53野生型胃癌患者的生存率显著低于TP53突变型患者。与低mRNA表达的TP53突变型胃癌患者相比，低mRNA表达的TP53野生型患者的总生存率更低。TP53野生型胃癌患者的死亡风险是TP53突变型胃癌患者的1.395倍。TP53突变型胃癌患者的死亡风险与年龄无关，高龄不是危险因素。然而，TP53野生型胃癌患者的死亡风险随年龄增加，70岁以上患者的死亡风险是60岁以下患者的1.899倍。这些结果表明，TP53野生型老年胃癌患者的预后更差。

结论

我们的结果表明，GC中TP53突变状态与临床或分子类别显著相关，且TP53野生型GC患者的预后比TP53突变型患者更差。因此，我们的数据强调了区分TP53野生型以预测GC患者总体生存不良和无复发生存的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/cf0628b6efab/nihms-1750514-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/4192d1a8083f/nihms-1750514-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/423d1f61f080/nihms-1750514-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/1be8359954b1/nihms-1750514-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/c4f16cfb64f2/nihms-1750514-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/cf0628b6efab/nihms-1750514-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/4192d1a8083f/nihms-1750514-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/423d1f61f080/nihms-1750514-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/1be8359954b1/nihms-1750514-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/c4f16cfb64f2/nihms-1750514-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba0e/8694034/cf0628b6efab/nihms-1750514-f0005.jpg

相似文献

1
Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer.野生型TP53预示胃癌患者预后不良。
J Cancer Sci Clin Ther. 2021 Mar 18;5(1):134-153. doi: 10.26502/jcsct.50790107.
2
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.T1G3期移行性膀胱癌中FGFR3和Tp53突变：独立分布及与预后无关
Clin Cancer Res. 2005 Aug 1;11(15):5444-50. doi: 10.1158/1078-0432.CCR-05-0122.
3
Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.TP53基因的突变谱可预测胃癌的临床病理特征及生存情况。
Oncotarget. 2016 Jul 5;7(27):42252-60. doi: 10.18632/oncotarget.9770.
4
Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.肺腺癌患者中 TP53 共突变状态与 EGFR 突变联合的预后价值。
J Cancer Res Clin Oncol. 2020 Nov;146(11):2851-2859. doi: 10.1007/s00432-020-03340-5. Epub 2020 Aug 2.
5
Genomic landscape and prognosis of patients with -mutated non-small cell lung cancer.具有特定突变的非小细胞肺癌患者的基因组格局与预后
Ann Transl Med. 2022 Feb;10(4):188. doi: 10.21037/atm-22-412.
6
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).TP53共突变对表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的预后和预测作用。
Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.
7
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.基于非基因毒性药物Nutlin-3激活TP53的体外功能试验检测慢性淋巴细胞白血病中的TP53功能障碍：临床应用建议
J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83.
8
Mutational separation and clinical outcomes of and in gastric cancer.胃癌中[具体基因名称1]和[具体基因名称2]的突变分离及临床结局
World J Gastrointest Surg. 2023 Dec 27;15(12):2855-2865. doi: 10.4240/wjgs.v15.i12.2855.
9
Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts.胃癌的分子亚型结合了遗传和表观遗传异常，提供了不同的临床病理特征和预后影响。
Hum Mutat. 2019 Mar;40(3):347-354. doi: 10.1002/humu.23700. Epub 2019 Jan 15.
10
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.基因组注释风险模型在晚期肾细胞癌中的应用：一项回顾性队列研究。
Lancet Oncol. 2018 Dec;19(12):1688-1698. doi: 10.1016/S1470-2045(18)30648-X. Epub 2018 Nov 8.

引用本文的文献

1
Immunohistochemical-Based Molecular Typing of ACRG Combined With Immune-Associated PD-L1 Expression Can Predict the Prognosis of Gastric Cancer.基于免疫组织化学的ACRG分子分型联合免疫相关PD-L1表达可预测胃癌预后。
Cancer Med. 2025 Apr;14(7):e70863. doi: 10.1002/cam4.70863.
2
PLASMA: Partial LeAst Squares for Multiomics Analysis.血浆：用于多组学分析的偏最小二乘法
Cancers (Basel). 2025 Jan 17;17(2):287. doi: 10.3390/cancers17020287.
3
Characterize molecular signatures and establish a prognostic signature of gastric cancer by integrating single-cell RNA sequencing and bulk RNA sequencing.

本文引用的文献

1
SASP: Tumor Suppressor or Promoter? Yes!柳氮磺胺吡啶：肿瘤抑制因子还是促进因子？答案是！两者皆是！
Trends Cancer. 2016 Nov;2(11):676-687. doi: 10.1016/j.trecan.2016.10.001. Epub 2016 Oct 24.
2
Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.TP53基因的突变谱可预测胃癌的临床病理特征及生存情况。
Oncotarget. 2016 Jul 5;7(27):42252-60. doi: 10.18632/oncotarget.9770.
3
NCI-MATCH trial pushes cancer umbrella trial paradigm.美国国立癌症研究所匹配试验推动癌症综合试验模式。
通过整合单细胞RNA测序和批量RNA测序来表征胃癌的分子特征并建立预后特征。
Discov Oncol. 2024 Jul 24;15(1):301. doi: 10.1007/s12672-024-01168-w.
4
Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration.胃癌的分子分类：呼吁跨学科合作。
Int J Mol Sci. 2024 Feb 24;25(5):2649. doi: 10.3390/ijms25052649.
5
Genomic analysis of matrix metalloproteinases affecting the prognosis and immunogenic profile of gastric cancer.影响胃癌预后和免疫原性特征的基质金属蛋白酶的基因组分析
Front Genet. 2023 Apr 18;14:1128088. doi: 10.3389/fgene.2023.1128088. eCollection 2023.
6
Molecular Classification of Hepatocellular Carcinoma Using Wnt-Hippo Signaling Pathway-Related Genes.利用Wnt-Hippo信号通路相关基因对肝细胞癌进行分子分类
Cancers (Basel). 2022 Sep 21;14(19):4580. doi: 10.3390/cancers14194580.
7
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.根据 TP53 突变状态对胃和胃食管交界处腺癌患者的肿瘤 DNA 测序结果进行评估。
Oncologist. 2022 Apr 5;27(4):307-313. doi: 10.1093/oncolo/oyac018.
Nat Rev Drug Discov. 2015 Aug;14(8):513-5. doi: 10.1038/nrd4694.
4
Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma.胃腺癌的遗传学和分子发病机制。
Gastroenterology. 2015 Oct;149(5):1153-1162.e3. doi: 10.1053/j.gastro.2015.05.059. Epub 2015 Jun 12.
5
Comprehensive molecular characterization of gastric adenocarcinoma.胃腺癌的全面分子特征分析。
Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23.
6
Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.弥漫型胃癌中 RHOA 的复发性功能获得性突变。
Nat Genet. 2014 Jun;46(6):583-7. doi: 10.1038/ng.2984. Epub 2014 May 11.
7
Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.胃癌患者中p53状态与化疗反应的关系：一项荟萃分析。
PLoS One. 2014 Apr 16;9(4):e95371. doi: 10.1371/journal.pone.0095371. eCollection 2014.
8
DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology.癌症化疗中的DNA损伤剂：意外发现与化学生物学
Chem Biol. 2013 May 23;20(5):648-59. doi: 10.1016/j.chembiol.2013.04.007.
9
Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.2002 年在日本治疗的胃癌：JGCA 全国注册处 2009 年度报告。
Gastric Cancer. 2013 Jan;16(1):1-27. doi: 10.1007/s10120-012-0163-4. Epub 2012 Jun 23.
10
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.p53 介导的衰老会损害乳腺癌对化疗的凋亡反应和临床预后。
Cancer Cell. 2012 Jun 12;21(6):793-806. doi: 10.1016/j.ccr.2012.04.027.